Drug Trial Radar · NCT07229638
A IB/II Phase Clinical Study on the Safety, Tolerability, and Efficacy of SHR-9839(sc) in Combination Anti-tumor Therapy in Patients With Solid Tumors
Last checked: Nov 19, 2026Latest source record: Mar 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
70
Planned (sponsor's estimate)
Start
Feb 27, 2026
Primary completion
Apr 2027
Study completion Jun 2027
Sponsor
- Lead sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is an open-label, multi-center Phase IB/II clinical trial of SHR-9839(sc) combined with anti-tumor therapy in patients with advanced solid tumors, aimed at evaluating the safety, tolerability, and efficacy of SHR-9839(sc) in combination with anti-tumor therapy in patients with advanced solid tumors.
Conditions
- Solid Tumor
Interventions
SHR-9839(sc) For InjectionDrug
SHR-9839(sc) for injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-limiting toxicities (DLT)Time frame: 28 days.
- Adverse events (AEs)Time frame: 13 months.
- Recommended dose for expansion (RDE)Time frame: From the first dose to the last visit, about 13 months.
- Objective Response Rate (ORR)Time frame: From the first dose to the last visit, about 13 months.
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Nanjing Medical University, Jiangsu Provincial People's Hospital
Nanjing, Jiangsu, China · Recruiting
Fudan University Affiliated Cancer Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.